No Data
No Data
Suning Universal (000718.SZ): The controlling shareholder and some directors and supervisors completed a total shareholding of 10.2148 million shares.
Suning Universal (000718.SZ) announced that as of the close of trading on July 1, 2024, the actual controller of the company, some directors, supervisors, and senior management personnel (referred to as the "subject of this shareholding plan") increased a total of 10,214,800 shares of the company's shares in the secondary market by means of centralized bidding, accounting for 0.34% of the total share capital of the company, with a total shareholding amount of 21,178,700 yuan. This shareholding plan has been successfully implemented.
Suning Universal Co.,Ltd's (SZSE:000718) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
Individual Investors Are Suning Universal Co.,Ltd's (SZSE:000718) Biggest Owners and Were Hit After Market Cap Dropped CN¥364m
Suning Global (000718.SZ): In 2023, the company's medical and aesthetic business revenue was about 198 million yuan, with a gross profit margin of 49.71%
Gelonghui, May 22丨Suning Global (000718.SZ) said on the investor interactive platform that in 2023, the company's medical and aesthetic business revenue was about 198 million yuan, with a gross profit margin of 49.71%.
Suning Global (000718.SZ): Currently not engaged in synthetic biologics-related business
Gelonghui, May 20 | Suning Global (000718.SZ) said on the investor interactive platform that the company currently does not carry out synthetic biologics-related business. The company's subsidiaries Shenzhen Zhongke Huarui Biotechnology Co., Ltd. and Hunan Ruishengke Biotechnology Co., Ltd. focus on regenerative medicine biotechnology. Their stem cell exosome technology can be used for light medical and aesthetic projects such as facial anti-aging, intimate care, and hair regeneration.
Investors Can Find Comfort In Suning UniversalLtd's (SZSE:000718) Earnings Quality
No Data